WHO Highlights AISAP for Transforming Cardiac Care at Sheba Medical Center

The WHO report, titled "Bridging Theory and Practice," features AISAP as a primary case study for integrating artificial intelligence into complex health systems. Data from a prospective study at Sheba, published in Mayo Clinic Proceedings: Digital Health, demonstrate the system's impact on patient outcomes: among 660 evaluated patients, AI-guided scans uncovered 147 previously undocumented diagnoses. These findings directly influenced treatment decisions, triggering medication changes for 49 patients and necessitating interventional procedures for nine others.

Validated against formal echocardiography in a subset of 117 cases, the platform achieved 100% sensitivity for detecting significant left ventricular dysfunction. Robert Klempfner, Chief Medical Officer and co-founder of AISAP, noted that the recognition validates the company’s ability to bring specialist-level diagnostics to any clinician. Beyond the initial study, the technology has seen broad adoption at Sheba, with over 3,000 scans performed by 150 trained clinicians across six hospital departments as of mid-2025. Since receiving FDA clearance in September 2024 for its AISAP CARDIO V1.0 system, the company has expanded its research partnerships to include institutions such as Stanford, the Mayo Clinic, and Mass General Brigham.